Compounds > n-succinimidyl-5-iodo-3-pyridinecarboxylic acid

Page last updated: 2024-12-07

n-succinimidyl-5-iodo-3-pyridinecarboxylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID Source	ID
PubMed CID	125509
SCHEMBL ID	893647
MeSH ID	M0189022

Synonyms (9)

Synonym
sipc
(2,5-dioxopyrrolidin-1-yl) 5-iodopyridine-3-carboxylate
n-succinimidyl-5-iodo-3-pyridinecarboxylic acid
2,5-pyrrolidinedione, 1-(((5-iodo-3-pyridinyl)carbonyl)oxy)-
131865-61-7
SCHEMBL893647
n-succinimidyl 5-iodo-3-pyridinecarboxylate
DTXSID50927374
1-[(5-iodopyridine-3-carbonyl)oxy]pyrrolidine-2,5-dione

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	3 (27.27)	18.2507
2000's	1 (9.09)	29.6817
2010's	0 (0.00)	24.3611
2020's	7 (63.64)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.65

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	11.65 (24.57)
Research Supply Index	2.56 (2.92)
Research Growth Index	4.21 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (11.65)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	12 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
urea pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.	2	1	0	isourea; monocarboxylic acid amide; one-carbon compound	Daphnia magna metabolite; Escherichia coli metabolite; fertilizer; flour treatment agent; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
tyramine [no description available]	2.4	2	0	monoamine molecular messenger; primary amino compound; tyramines	EC 3.1.1.8 (cholinesterase) inhibitor; Escherichia coli metabolite; human metabolite; mouse metabolite; neurotransmitter
cellobiose beta-cellobiose : A cellobiose with beta configuration at the reducing-end glucose residue.	2	1	0	cellobiose	epitope
1,3,4,6-tetrachloro-3 alpha,6 alpha-diphenylglycoluril 1,3,4,6-tetrachloro-3 alpha,6 alpha-diphenylglycoluril: reagent for protein iodinations; structure	2	1	0
silicon phthalocyanine pc4 [no description available]	3.46	4	0
phthalocyanine phthalocyanine : A tetrapyrrole fundamental parent that consists of four isoindole-type units, with the connecting carbon atoms in the macrocycle replaced by nitrogen.	2.6	1	0	phthalocyanines; tetrapyrrole fundamental parent

Condition	Indicated	Relationship Strength	Studies	Trials
HPV Infection [description not available]	0	2.41	1	0
Cancer of Cervix [description not available]	0	2.41	1	0
Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX.	0	2.41	1	0
Papillomavirus Infections Neoplasms of the skin and mucous membranes caused by papillomaviruses. They are usually benign but some have a high risk for malignant progression.	0	2.41	1	0
Anoxemia [description not available]	0	4.21	9	0
Benign Neoplasms [description not available]	0	4.21	9	0
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	0	4.21	9	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	0	4.21	9	0
Injury, Ischemia-Reperfusion [description not available]	0	2.6	1	0
Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.	0	2.6	1	0
Breast Cancer [description not available]	0	2.6	1	0
Breast Neoplasms Tumors or cancer of the human BREAST.	0	2.6	1	0
2019 Novel Coronavirus Disease [description not available]	0	2.6	1	0
Glial Cell Tumors [description not available]	0	2.4	2	0
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	0	2.4	2	0
Cancer of Ovary [description not available]	0	2	1	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	0	2	1	0